Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.63 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.59 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.54 |
| ▸ | CALCA | P06881 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246452 | 0.92 | CALCRL (0.72) | CALCRLRAMP1CALCA | |
| SCHEMBL10246447 | 0.87 | CALCRL (0.61) | CALCRLRAMP1ADM2CALCA | |
| SCHEMBL10246567 | 0.86 | CALCRL (0.71) | CALCRLRAMP1CALCA | |
| SCHEMBL10246193 | 0.85 | CALCRL (0.60) | CALCRLRAMP1ADM2CALCA | |
| SCHEMBL14669004 | 0.82 | CALCRL (0.42) | CALCRLRAMP1 | |
| SCHEMBL10246198 | 0.82 | CALCRL (0.74) | CALCRLRAMP1CALCA | |
| SCHEMBL10246575 | 0.81 | CALCRL (0.59) | CALCRLRAMP1ADM2CALCA | |
| SCHEMBL10246574 | 0.81 | CALCRL (0.69) | CALCRLRAMP1ADM2CALCA | |
| SCHEMBL2067912 | 0.81 | CALCRL (0.72) | CALCRLRAMP1CALCA | |
| SCHEMBL10246196 | 0.81 | CALCRL (0.58) | CALCRLRAMP1ADM2CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAMP1 51/4885ADM2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.